Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company's primary focus is on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. The company was founded in 1975 and is headquartered in Flint, Michigan.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorRetail/Wholesale
SymbolNYSE:DPLO
CUSIPN/A
Phone888-720-4450
Debt
Debt-to-Equity Ratio0.58
Current Ratio0.91
Quick Ratio0.63
Price-To-Earnings
Trailing P/E Ratio22.68
Forward P/E Ratio21.90
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.49 billion
Price / Sales0.32
Cash Flow$1.8441 per share
Price / Cash10.33
Book Value$10.88 per share
Price / Book1.75
Profitability
EPS (Most Recent Fiscal Year)$0.84
Net Income$15.51 million
Net Margins0.06%
Return on Equity7.86%
Return on Assets3.39%
Miscellaneous
Employees2,419
Outstanding Shares74,410,000
Market Cap$1.41 billion
Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions
What is Diplomat Pharmacy's stock symbol?
Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."
How were Diplomat Pharmacy's earnings last quarter?
Diplomat Pharmacy Inc (NYSE:DPLO) released its quarterly earnings data on Monday, August, 6th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.23 by $0.06. The business earned $1.42 billion during the quarter, compared to the consensus estimate of $1.42 billion. Diplomat Pharmacy had a net margin of 0.06% and a return on equity of 7.86%. The firm's quarterly revenue was up 25.8% on a year-over-year basis. During the same period last year, the business posted $0.25 earnings per share. View Diplomat Pharmacy's Earnings History.
When is Diplomat Pharmacy's next earnings date?
What price target have analysts set for DPLO?
11 Wall Street analysts have issued 12-month price targets for Diplomat Pharmacy's stock. Their forecasts range from $18.00 to $35.00. On average, they expect Diplomat Pharmacy's stock price to reach $26.90 in the next twelve months. This suggests a possible upside of 41.2% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy.
What is the consensus analysts' recommendation for Diplomat Pharmacy?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Diplomat Pharmacy.
Who are some of Diplomat Pharmacy's key competitors?
Who are Diplomat Pharmacy's key executives?
Diplomat Pharmacy's management team includes the folowing people:
- Mr. Joel Saban, Pres (Age 50)
- Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 66)
- Mr. Atul Kavthekar, CFO & Treasurer
- Mr. Gary Rice M.B.A., M.S., R.Ph., RPh, MS, MBA, CSP, Exec. VP of Operations (Age 60)
- Mr. Brian Thomas Griffin, CEO & Chairman (Age 59)
Has Diplomat Pharmacy been receiving favorable news coverage?
Media coverage about DPLO stock has been trending somewhat negative this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Diplomat Pharmacy earned a media and rumor sentiment score of -0.01 on Accern's scale. They also assigned media headlines about the company an impact score of 45.15 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Diplomat Pharmacy.
Who are Diplomat Pharmacy's major shareholders?
Diplomat Pharmacy's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.76%), Janus Henderson Group PLC (7.26%), FMR LLC (3.78%), Frontier Capital Management Co. LLC (2.59%), Victory Capital Management Inc. (1.67%) and Dimensional Fund Advisors LP (1.64%). Company insiders that own Diplomat Pharmacy stock include Atheer A Kaddis, Atul Kavthekar, Jeffrey G Park, Joel Saban, Philip R Hagerman and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.
Which institutional investors are selling Diplomat Pharmacy stock?
DPLO stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Phocas Financial Corp., State of Wisconsin Investment Board, Fred Alger Management Inc., Cambridge Investment Research Advisors Inc., Dimensional Fund Advisors LP, Capital Investment Advisory Services LLC and Redwood Investments LLC. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Jeffrey G Park, Philip R Hagerman and Shawn Tomasello. View Insider Buying and Selling for Diplomat Pharmacy.
Which institutional investors are buying Diplomat Pharmacy stock?
DPLO stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Janus Henderson Group PLC, Victory Capital Management Inc., Rice Hall James & Associates LLC, BlackRock Inc., Pier Capital LLC, Cortina Asset Management LLC and Engineers Gate Manager LP. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.
How do I buy shares of Diplomat Pharmacy?
Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Diplomat Pharmacy's stock price today?
One share of DPLO stock can currently be purchased for approximately $19.05.
How big of a company is Diplomat Pharmacy?
Diplomat Pharmacy has a market capitalization of $1.41 billion and generates $4.49 billion in revenue each year. The company earns $15.51 million in net income (profit) each year or $0.84 on an earnings per share basis. Diplomat Pharmacy employs 2,419 workers across the globe.
How can I contact Diplomat Pharmacy?
Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]
MarketBeat Community Rating for Diplomat Pharmacy (NYSE DPLO)
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe DPLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
